viimane versioon :
29/10/2024
Infostab
ingredientide nimekiri
nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
uurimisrühmad
valistab
plakat
Sidemed
sponsorid
Autor
Kasutusjuhend
ajakiri
Palonosetron hydrochloride
keemiline struktuur
Kaubanduslikud nimed erinevates maades
Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist
Aloxi
Ameerika ühendriigid, Austria, Belgia, Hispaania, Holland, Iirimaa, Island, Itaalia, Jaapan, Kanada, Kreeka, Luksemburg, Malaisia, Norra, Poola, Portugal, Rootsi, Rumeenia, Saksamaa, Soome, Suurbritannia, Sveits, Taani, Türgi, Ungari
Chepatron
India
Cinvex
Türgi
Factoket
Mehhiko
Lotisa
Türgi
Onicit
Ecuador, Itaalia, Kolumbia, Maroko, Tšiili
Palohalt
Maroko, Tšiili
Paloject
Türgi
Palonosetron
Belgia, Ecuador, Hispaania, Prantsusmaa, Saksamaa, Suurbritannia, Sveits, Tšiili
Palostar
India
Palzen
India
Vinaltro
Mehhiko
Viqet
Mehhiko
Vonaxi
Türgi
Viited : Palonosetron hydrochloride
tüüp
avaldamine
1932
ajaleht
Trissel LA, Zhang Y.
Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate.
Int J Pharm Compound 2004 ; 8,5: 398-403.
1936
ajaleht
Trissel LA, Xu QA.
Physical and chemical stability of palonosetron HCl in 4 infusion solusions.
Ann Pharmacotherapy 2004 ; 38: 1608-1611.
1940
ajaleht
Xu QA, Trissel LA.
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1950
ajaleht
Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
1955
ajaleht
Trissel LA, Zhang Y.
Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration.
Ann Pharmacotherapy 2005 ; 39: 280-283.
1975
ajaleht
Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 235-237.
1976
ajaleht
Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241.
2009
ajaleht
Trissel LA, Zhang Y.
Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2016
ajaleht
Xu QA, Trissel LA.
Compatibility of palonosetron with cyclophosphamide and with ifosfamide during Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 1998-2000.
2107
ajaleht
Trissel LA, Zhang Y, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.
Int J Pharm Compound 2006 ; 10: 234-236.
2179
ajaleht
Trusley C, Ben M, Kupiec TC, Trissel LA.
Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration.
Int J Pharm Compound 2007 ; 11, 1: 82-85.
2196
ajaleht
Trissel LA, Trusley C, Ben M, Kupiec TC.
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration.
Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2214
ajaleht
Ben M, Trusley C,Kupiec T.C, Trissel L.A.
Palonosetron hydrochloride compatibility and stability with three beta-lactam antibiotics during simulated Y-site administration.
Int J Pharm Compound 2007 ; 11, 6: 520-524.
2227
ajaleht
Trusley C, Ben M, Kupiec TC, Trissel LA.
Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 2: 156-160.
2228
ajaleht
Kupiec T, Ben M, Trusley C, Trissel LA.
Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12,2: 170-173.
2279
ajaleht
Kupiec T, Trusley C, Ben M, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2281
ajaleht
Ben M, Kupiec T, Trusley C, Trisel LA.
Compatibility and stability of palonosetron hydrochloride with lactated Ringer's, Hetastarch in lactated electrolyte, an mannitol injections during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 5: 460-462.
2286
ajaleht
Ben M, Trusley C, Kupiec TC, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12, 4: 368-371.
2312
ajaleht
Trissel L.A, Trusley C, Kupiec T.C, Ben M.
Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration.
Int J Pharm Compound 2009 ; 13, 1: 78-80.
3459
ajaleht
Sun S, Schaller J, Placek J, Duersch B.
Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3928
ajaleht
Wu G, Yeung S, Chen F.
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride.
Int J Pharm Compound 2017 ; 21, 1: 76-82.
3981
ajaleht
He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D.
Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study
EJHP 2017 ;24:162?166
4062
ajaleht
Wu George, Powers Dan, Yeung S, Chen F, Neelon K.
Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection.
Int J Pharm Compound 2018 ;22,1:76-85
4310
ajaleht
Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M.
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.
Mentions Légales